|
|
Gene Symbol |
IGF1R |
|
Aliases |
CD221, IGFIR, IGFR, JTK13 |
|
Entrez Gene ID |
|
|
Gene Name |
Insulin like growth factor 1 receptor |
|
Chromosomal Location |
15q26.3 |
|
HGNC ID |
|
|
Summary |
This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2014]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
|
|
e!Ensembl
|
Gene Ontology (GO)
GO ID |
Ontology |
Function |
Evidence |
Reference |
GO:0006955 |
Biological process |
Immune response |
IMP |
16886151 |
GO:0007165 |
Biological process |
Signal transduction |
TAS |
3003744 |
GO:0007169 |
Biological process |
Transmembrane receptor protein tyrosine kinase signaling pathway |
IBA |
21873635 |
GO:0008284 |
Biological process |
Positive regulation of cell proliferation |
IMP |
12138094 |
GO:0008286 |
Biological process |
Insulin receptor signaling pathway |
ISS |
19406747 |
GO:0014065 |
Biological process |
Phosphatidylinositol 3-kinase signaling |
IC |
7541045 |
GO:0014068 |
Biological process |
Positive regulation of phosphatidylinositol 3-kinase signaling |
IBA |
21873635 |
GO:0030335 |
Biological process |
Positive regulation of cell migration |
IMP |
12138094 |
GO:0038083 |
Biological process |
Peptidyl-tyrosine autophosphorylation |
IMP |
19545541 |
GO:0042593 |
Biological process |
Glucose homeostasis |
IBA |
21873635 |
GO:0043066 |
Biological process |
Negative regulation of apoptotic process |
IDA |
12556535 |
GO:0043243 |
Biological process |
Positive regulation of protein complex disassembly |
ISS |
19406747 |
GO:0043410 |
Biological process |
Positive regulation of MAPK cascade |
IBA |
21873635 |
GO:0046328 |
Biological process |
Regulation of JNK cascade |
IBA |
21873635 |
GO:0046328 |
Biological process |
Regulation of JNK cascade |
IDA |
12556535 |
GO:0046777 |
Biological process |
Protein autophosphorylation |
IDA |
1846292, 7679099, 11162456 |
GO:0048009 |
Biological process |
Insulin-like growth factor receptor signaling pathway |
IBA |
21873635 |
GO:0048009 |
Biological process |
Insulin-like growth factor receptor signaling pathway |
IDA |
7679099 |
GO:0048015 |
Biological process |
Phosphatidylinositol-mediated signaling |
IDA |
7692086 |
GO:0048856 |
Biological process |
Anatomical structure development |
IBA |
21873635 |
GO:0051262 |
Biological process |
Protein tetramerization |
IDA |
1846292 |
GO:0051389 |
Biological process |
Inactivation of MAPKK activity |
IDA |
12556535 |
GO:0051897 |
Biological process |
Positive regulation of protein kinase B signaling |
IBA |
21873635 |
GO:0071333 |
Biological process |
Cellular response to glucose stimulus |
IBA |
21873635 |
GO:0097062 |
Biological process |
Dendritic spine maintenance |
ISS |
19406747 |
GO:0097242 |
Biological process |
Amyloid-beta clearance |
IMP |
19406747 |
GO:0120162 |
Biological process |
Positive regulation of cold-induced thermogenesis |
ISS |
26910308 |
GO:1904646 |
Biological process |
Cellular response to amyloid-beta |
IGI |
22635104 |
GO:0005887 |
Cellular component |
Integral component of plasma membrane |
IBA |
21873635 |
GO:0005887 |
Cellular component |
Integral component of plasma membrane |
IC |
7679099 |
GO:0005899 |
Cellular component |
Insulin receptor complex |
IBA |
21873635 |
GO:0016020 |
Cellular component |
Membrane |
IDA |
8452530 |
GO:0030424 |
Cellular component |
Axon |
IBA |
21873635 |
GO:0035867 |
Cellular component |
Alphav-beta3 integrin-IGF-1-IGF1R complex |
IDA |
19578119 |
GO:0043231 |
Cellular component |
Intracellular membrane-bounded organelle |
IDA |
8452530 |
GO:0043235 |
Cellular component |
Receptor complex |
IBA |
21873635 |
GO:0043235 |
Cellular component |
Receptor complex |
IDA |
23382219 |
GO:0004713 |
Molecular function |
Protein tyrosine kinase activity |
IDA |
7679099, 11162456 |
GO:0004713 |
Molecular function |
Protein tyrosine kinase activity |
IMP |
11884589 |
GO:0004714 |
Molecular function |
Transmembrane receptor protein tyrosine kinase activity |
IBA |
21873635 |
GO:0005009 |
Molecular function |
Insulin-activated receptor activity |
IBA |
21873635 |
GO:0005010 |
Molecular function |
Insulin-like growth factor-activated receptor activity |
IDA |
7679099 |
GO:0005158 |
Molecular function |
Insulin receptor binding |
IDA |
8452530 |
GO:0005515 |
Molecular function |
Protein binding |
IPI |
7541045, 7589433, 7642582, 8452530, 8603569, 8895367, 8999839, 9480911, 9727029, 10026153, 11724822, 12482592, 12556535, 15878855, 15976035, 15998644, 16926280, 17360667, 20195357, 21645859, 21685939, 22245152, 22261717, 25241761, 25416956, 26027733, 26692333 |
GO:0005520 |
Molecular function |
Insulin-like growth factor binding |
IDA |
1846292, 7679099 |
GO:0031994 |
Molecular function |
Insulin-like growth factor I binding |
IDA |
19578119 |
GO:0031994 |
Molecular function |
Insulin-like growth factor I binding |
IPI |
8452530 |
GO:0042802 |
Molecular function |
Identical protein binding |
IPI |
11448933, 17586502, 21645859 |
GO:0043548 |
Molecular function |
Phosphatidylinositol 3-kinase binding |
IPI |
7541045 |
GO:0043559 |
Molecular function |
Insulin binding |
IPI |
8452530 |
GO:0043560 |
Molecular function |
Insulin receptor substrate binding |
IBA |
21873635 |
GO:0043560 |
Molecular function |
Insulin receptor substrate binding |
IPI |
7541045 |
|
Protein Information |
|
Protein Name |
Insulin-like growth factor 1 receptor, IGF-I receptor, soluble IGF1R variant 1, soluble IGF1R variant 2 |
|
Function |
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.; When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin |
|
|
|
|
|
UniProt |
|
|
PDB |
1IGR, 1JQH, 1K3A, 1M7N, 1P4O, 2OJ9, 2ZM3, 3D94, 3F5P, 3I81, 3LVP, 3LW0, 3NW5, 3NW6, 3NW7, 3O23, 3QQU, 4D2R, 4XSS, 5FXQ, 5FXR, 5FXS, 5HZN, 5U8Q, 5U8R |
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
|
P01909 |
P01909 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Congenital diaphragmatic hernia |
|
Microcephaly |
|
Russell-Silver syndrome |
|
Resistance to Insulin-Like Growth Factor I |
|
Endocrine System Diseases |
PCOS |
|
Immune System Diseases |
Juvenile arthritis |
|
Still Disease |
|
Neoplasms |
Breast Cancer |
|
Skin Cancer |
|
Liver Cancer |
|
Endometrial Cancer |
|
Adrenal Cancer |
|
Nervous System Diseases |
Neuropathy |
|
Parkinson Disease |
|
Psychiatric/Brain disorders |
Lewy Body Disease |
|
Senile Dementia |
|
Alzheimer Disease |
|
Reproductive disorders |
Endometriosis |
|
Preeclampsia |
|
Respiratory Tract Diseases |
Respiratory Failure |
|
|
References |
|
|
Samoto T, Maruo T, Matsuo H, Katayama K, Barnea E R, Mochizuki M |
Department of Obstetrics and Gynecology, Kobe University School of Medicine, Japan. |
Endocr J. 1993 Aug;40(4):413-24. |
Abstract
In the ovary, insulin and insulin-like growth factor-I (IGF-I) act synergistically with FSH to augment estrogen production by granulosa cells and with LH to augment androgen production by thecal stromal cells. It is also evident that insulin resistance is common in patients with polycystic ovary syndrome (PCO). Thus, in the present study we investigated the expression of insulin and IGF-I receptors in PCO ovaries and compared them with those in normal ovaries. Ovarian tissues were obtained from four PCO patients undergoing wedge resection, and from six patients who underwent radical hysterectomy. Immunohistochemical staining for insulin and IGF-I receptors was performed by avidin/biotin immunoperoxidase techniques. In normal ovaries, the expression of insulin and IGF-I receptors in follicular compartment became apparent in the preantral follicle stage and augmented with the follicular growth, while the stromal cells, regardless of the follicle stage, possessed insulin and IGF-I receptors. In PCO ovaries associated with hyperinsulinemia, no expression of insulin receptors was detected in granulosa or thecal stromal cells, while IGF-I receptor expression increased in thecal stromal cells but decreased in granulosa cells compared to those in normal ovaries. However, in PCO ovaries from patients without hyperinsulinemia, insulin receptor expression was apparent in both granulosa and thecal stromal cells, with a similar intensity to that observed in normal ovaries, while IGF-I receptor expression was negligible in granulosa cells but sustained in thecal stromal cells. These findings suggest that decreased expression of insulin receptors in PCO ovaries associated with hyperinsulinemia may be secondary to receptor down regulation, whereas defective expression in granulosa cells along with elevated or persisted expression in thecal stromal cells of IGF-I receptors may be common in PCO ovaries and contribute to the endocrine profiles of PCO in which varying degrees of hyperandrogenism is a predominant feature. |
|
|
|
|
| © 2019, Biomedical Informatics Centre, NIRRH |
National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai-400 012
Tel: 91-22-24192104, Fax No: 91-22-24139412
|